Hiroaki Akamatsu
Prof Hiroaki Akamatsu, MD, PhD is an expert in Oncology at Wakayama Medical University (Japan). As of October 2026, ScienceLeadR ranks Hiroaki Akamatsu in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Hiroaki Akamatsu has authored 403 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 6 of them ongoing. SLR score: 1,588 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pulmonology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2009 - 2026
Number : 403
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study. PMID 42762420 — cells, lung, safety, neoplasms, drug therapy, drug-related side effects and adverse reactions, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy | Int J Clin Oncol | 2026 | 0 |
| Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. PMID 42929675 — progression-free survival, disease progression, carcinoma, non-small-cell lung, drug-related side effects and adverse reactions, therapeutics | N Engl J Med Top journal | 2026 | 0 |
| Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI-Platinum Therapy (WJOG14120L). PMID 42816458 — safety, carcinoma, squamous cell, neoplasms, carcinoma, non-small-cell lung, drug therapy, therapeutics | Cancer Sci | 2026 | 0 |
| Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC. PMID 42189883 — cells, blood, carcinoma, non-small-cell lung, biomarkers, therapeutics | Clin Cancer Res | 2026 | 0 |
| Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial. PMID 42664473 — cells, lung, disease-free survival, safety, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, medical oncology, chemotherapy | J Clin Oncol Top journal | 2026 | 2 |
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Neladalkib (NVL 655) for TKI naive Patients With Advanced ALK Positive NSCLC NCT06765109 — cells, lung, lymphoma, neoplasms, carcinoma, non-small-cell lung, tablets, capsules, lung neoplasms, small cell lung carcinoma, therapeutics, anaplastic lymphoma kinase, lung diseases, carcinoma | Phase 3 | Recruiting | 2025 |
| A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C positive Advanced or Metastatic Non Small Cell Lung Cancer NCT06497556 — cells, lung, safety, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, mutation, carcinoma | Phase 3 | Active not recruiting | 2024 |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer NCT05740566 — cells, lung, neoplasms, drug therapy, lung neoplasms, small cell lung carcinoma, topotecan, chemotherapy, carcinoma | Phase 3 | Active not recruiting | 2023 |
| A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR) Mutated Advanced or Metastatic Non small Cell Lung Cancer NCT05388669 — injections, cells, epidermal growth factor, lung, growth, neoplasms, carcinoma, non-small-cell lung, tablets, drug therapy, lung neoplasms, receptors, growth factor, small cell lung carcinoma, hyaluronoglucosaminidase, chemotherapy, carcinoma | Phase 3 | Active not recruiting | 2022 |
| A Study of Neladalkib (NVL 655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE 1) NCT05384626 — safety, itraconazole, pharmaceutical preparations, lymphoma, neoplasms, carcinoma, non-small-cell lung, tablets, midazolam, solutions, neoplasm metastasis, anaplastic lymphoma kinase, mutation, pharmacokinetics | Phase 1/Phase 2 | Recruiting | 2022 |
LeadR Networks
Main global connection map